Estrogen repalcement is an important part of the preventive health care of postmenopaulsal women. The utilizaiton of estrogens for the relief of menopausal complaints, such as atrophic vaginitis and vasomotor symptoms, and the prevention of osteoporosis is well established and may reduce the risk of cononary artery disease.
Despiet these benefit, many women are reluctant to use cyclic estrogen/progestin replacement therapy because of the problems of vaginal bleeding and the risk of endometrial cancer.
Furthermlore, progestin related side effects such as breast tenderness, headache, nausea, abdominal bloating and depression are additional reasons for patient dissatisfiaction, with cyclic therapy.
Continuous regimens of estrogen-progesterone have recently been favored over sequential regimens becuase of a lower incidence of withdrawal bleeding.
Therefore to determine the effect of different doses of progestin on lipid profiles and bone mineral density, we studied the daily continuous estrogen/progestine therapy in post menopausal women during a 1-year porspective trial.
The results were as follows:
1) The changes of serum cholesteral after hormone therapy in group I, II, and III decreased by 1.9%, 6.4% and 0.2% after one year, but the difference of changes between three groups was not statisitically significant.
2) The changes of serum LDL-cholesterol after hormone therapy in group I, II and III decreased by 22.1%, 19.7% and 15.5% after one year(p＜0.05) but the difference of changes between three groups was not statistically significant.
3) The changes of serum HDL-cholesterol after hormone replacement therapy in group I, II and III increased significantly by 16%, 15% and 10% after one year but the difference of changes between three groups was not statistically significant.
4) Teh changes of serum triglyceride after hormone replacement therapy in three groups increased 22%, 6% and decreased 22% but the difference of changes between three groups was not statistically significant.
5) The changes of bone mineral density of femur after hormone replacement therapy in three groups were not statistically significant.
6) The changes of bone mineral density of vertebrae after hormone repalcement terapy increased by 2.8%, 1.2% adn 0.2% after one year, but the differences were not statistically significant.
|